1. DealBook: 2 Banks Forged in Crisis, CIT and OneWest, Are Set to Merge, to a Big Payoff

    The CIT Group, which is run by John A. Thain, has agreed to acquire the parent company of OneWest Bank for $3.4 billion in cash and stock.

  2. DealBook: Fed Is Said to Criticize Deutsche Bank’s Oversight and Reporting Efforts

    A lawyer for a former employee of the bank said the Federal Reserve Bank of New York told the German bank of its findings in December.

  3. Microsoft’s Profits Slide on Mobile, but Its Cloud Flourishes

    Revenue at Microsoft was slightly higher than analysts expected, but earnings were 5 cents a share lower.

  4. Despite Anger Over Downed Jetliner, Europe Shies Away From Sanctions on Russia

    Foreign ministers had been seen as unlikely to impose tough new measures immediately, for fear of jeopardizing an independent search of the crash site of the Malaysia Airlines jet.

  5. Apple Reports $7.7 Billion Profit on Strong iPhone Sales

    Sales for the smartphone grew even in a time of year when smartphone sales are expected to be slow.

  6. DealBook: Judge Orders Argentina and Funds to Negotiate

    The judge has forbidden Argentina from paying creditors who accepted its long-ago restructuring, if the country has not satisfied the holdouts. Without a deal, the country faces default on July 30.

  7. Airlines Suspend Flights to Israel After Hamas Rocket Falls Near Main Airport

    After a rocket fell near Ben-Gurion airport outside Tel Aviv, the Federal Aviation Administration told American carriers to halt service for 24 hours, and some other airlines followed suit.

  8. An Austrian Company in Gazprom's Grip

    As the European Union weighs sanctions against Russia, the Austrian energy firm OMV is caught in a bind.

  9. Square Feet: The Top Properties in Hong Kong Housing Resist Market Forces

    While cooling measures have affected most real estate, the very rich are holding onto the city’s most expensive homes.

  10. Economic Scene: A Dearth in Innovation for Key Drugs

    While researchers pursue high-cost remedies for rare ailments, development of broadly useful drugs like antibiotics is lagging.